```
$
FILE 'MEDLINE'
FILE 'JAPIO'
FILE 'BIOSIS'
FILE 'SCISEARCH'
FILE 'WPIDS'
FILE 'CAPLUS'
FILE 'EMBASE'
=> s g-protein coupled receptor or g protein coupled receptor or gpcr
   4 FILES SEARCHED...
L1       38111 G-PROTEIN COUPLED RECEPTOR OR G PROTEIN COUPLED RECEPTOR OR GPCR

=> s l1 and (ebi-2 or ebi 2 or ebi 2)
   5 FILES SEARCHED...
L2           5 L1 AND (EBI-2 OR EBI 2 OR EBI 2)

=> l1 and 209003
L3           1 L1 AND 209003

=> l2 and (antibody or antibodies)
L4           3 L2 AND (ANTIBODY OR ANTIBODIES)

=> dup rem l2
PROCESSING COMPLETED FOR L2
L5           4 DUP REM L2 (1 DUPLICATE REMOVED)

=> dup rem l4
PROCESSING COMPLETED FOR L4
L6           2 DUP REM L4 (1 DUPLICATE REMOVED)

=> d l5 ibib abs 1-4

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:        2001:869734  CAPLUS
DOCUMENT NUMBER:         136:367316
TITLE:                   Distinct gene expression profiling in chronic
                         lymphocytic leukemia with 11q23 deletion
AUTHOR(S):               Aalto, Y.; El-Rifai, W.; Vilpo, L.; Ollila, J.; Nagy,
                         B.; Vihinen, M.; Vilpo, J.; Knuutila, S.
CORPORATE SOURCE:        Department of Medical Genetics, Haartman Institute and
                         Helsinki University Central Hospital, University of
                         Helsinki, Helsinki, Finland
SOURCE:                  Leukemia (2001), 15(11), 1721-1728
                         CODEN: LEUKED; ISSN: 0887-6924
PUBLISHER:               Nature Publishing Group
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with regard
     to its clin. course.  The limitations of the methods currently available
     for prognostic assessment in CLL do not allow accurate prediction of the
     risk of disease progression in individual patients.  The recently
     developed cDNA array technique provides a unique opportunity to study gene
     expression in various malignancies.  To identify new mol. markers for
     prognostication of CLL patients, we analyzed cDNA arrays by using
     hierarchical clustering and std. statistic t-test on 34 CLL patients.  We
     found significant expression differences in 78 genes compared to the ref.
     tonsillar B lymphocytes.  A cluster of genes, LCP1, PARP, BLR1, DEK, NPM,
     MCL1, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCL2, MNDA, PBX3,
     EBI2, TCF1, CGRP, CD14, IL8, GZMK, GPR17 and CD79B, was assocd. (P < 0.05)
     with the unfavorable 11q deletion and also with the unfavorable Binet
     stages B and C.  We present here gene expression profiling that is assocd.
     with CLL patients with the 11q23 deletion.  Many of the genes in the
     cluster have not previously been shown to be related to the initiation or
     progression of CLL.  These novel findings provide fundamental information
     for further attempts to understand the interaction of the clustered genes
     in the leukomogenesis of CLL in order to better design treatments aimed at
     specific mol. target(s).
REFERENCE COUNT:         33    THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 2 OF 4  WPIDS (C) 2003 THOMSON DERWENT     DUPLICATE 1
ACCESSION NUMBER:     1999-034722 [03]   WPIDS
DOC. NO. CPI:         C1999-010477
TITLE:                New isolated human   ***G***  -  ***protein***
                        ***coupled***     ***receptors***   - used to develop
                      products for treating e.g. asthma, Parkinson's disease,
                      heart failure, osteoporosis, hypertension, psychoses,
```

eating disorders or cancers.
DERWENT CLASS: B04 D16
INVENTOR(S): LI, Y; RUBEN, S M
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 22
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9850549	A2	19981112	(199903)*	EN	54
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP US					
US 6060272	A	20000509	(200030)		
EP 1007670	A2	20000614	(200033)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2002508657	W	20020319	(200222)		81
US 2002052043	A1	20020502	(200234)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9850549	A2		WO 1998-US9048	19980507
US 6060272	A		US 1997-852824	19970507
EP 1007670	A2		EP 1998-920965	19980507
			WO 1998-US9048	19980507
JP 2002508657	W		JP 1998-548332	19980507
			WO 1998-US9048	19980507
US 2002052043	A1	Cont of	US 1997-852824	19970507
		Cont of	US 2000-518383	20000303
			US 2001-827937	20010409

FILING DETAILS:

PATENT NO	KIND		PATENT NO
EP 1007670	A2	Based on	WO 9850549
JP 2002508657	W	Based on	WO 9850549
US 2002052043	A1	Cont of	US 6060272

PRIORITY APPLN. INFO: US 1997-852824 19970507; US 2000-518383 20000303; US 2001-827937 20010409
AN 1999-034722 [03] WPIDS
AB WO 9850549 A UPAB: 19990310
An isolated polynucleotide (PN) is claimed which comprises a PN having at least a 95% identity to a member selected from: (a) a PN encoding a polypeptide comprising amino acids 2 to 342 of a 342 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; (b) a PN encoding a polypeptide comprising amino acids 1 to 260 of a 276 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; and (c) the complement of (a) or (b).

Also claimed are:

(1) a recombinant vector comprising a PN as above which is DNA;

(2) a recombinant host cell comprising a PN as above which is DNA;

(3) an insolated PN comprising a PN having at least a 95% identity to a member selected from: (a) a PN encoding the same polypeptide encoded by a human cDNA in ATCC 209003; (b) a PN encoding the same polypeptide encoded by the human cDNA in ATCC 209004; and (c) the complement of (a) or (b);

(4) a recombinant vector comprising a PN as in (3) which is DNA;

(5) a recombinant host cell comprising a PN as in (3) which is DNA;

(6) an isolated polypeptide comprising a mature polypeptide having an amino acid sequence encoded by a PN which is at least 95% identical to a member selected from (a), (b) and (c) as in (A);

(7) an antibody against a polypeptide as in (6); (8) an antagonist against a polypeptide as in (6);

(8) a polynucleotide comprising nucleotides 226-1251 of a 2249 bp sequence given in the specification or nucleotides 2-827 of a 1737 bp sequence given in the specification (both encoding ***G*** ***protein*** ***coupled*** ***receptors***).

USE - (II) is a novel human Epstein-Barr Virus (EBV)-induced ***G*** - ***protein*** ***coupled*** ***receptor*** , designated ***EBI*** - ***2*** polypeptide. (IV) is a novel human endothelium-differentiation gene (EDG) like ***G*** - ***protein*** ***coupled*** ***receptor*** , designated EDG-1-like ***G*** - ***protein*** ***coupled*** ***receptor*** . Agonists for

G - ***protein*** ***coupled*** ***receptors*** can be used for the treatment of [redacted]. asthma, Parkinson's disease, [redacted]ute heart failure, hypotension, urinary retention and osteoporosis. Antagonists can be used for the treatment of e.g. hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, psychoses, depression, migraine, vomiting, stroke, eating disorders, migraine headaches, cancer and benign prostatic hypertrophy. The products can also be used for detection, diagnosis and drug screening.
Dwg.0/4

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:628002 CAPLUS
DOCUMENT NUMBER: 121:228002
TITLE: Genes induced in B lymphocytes upon infection by Epstein-Barr virus
INVENTOR(S): Birkenbach, Mark; Kieff, Elliot
PATENT ASSIGNEE(S): Brigham and Women's Hospital, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9412519	A1	19940609	WO 1993-US9636	19931008
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9453256	A1	19940622	AU 1994-53256	19931008
US 2002040133	A1	20020404	US 2001-929583	20010814

PRIORITY APPLN. INFO.: US 1992-980518 A 19921125
WO 1993-US9636 W 19931008
US 1994-352678 A3 19941130
US 2000-536954 A1 20000328

AB Genes induced in B lymphocytes upon infection with Epstein Barr virus (EBI genes) are cloned and characterized for use in the development of diagnostic reagents and studies of the development of infection are described. Three genes, EBI 1, ***EBI*** ***2*** and EBI 3 and the proteins encoded by them, probes for detection of infection, and antibodies to the proteins are described. A cDNA bank from Epstein-Barr virus (EBV) infected BL41 cells was differentially screened using probes from infected and uninfected cells to obtain 12 clones. Ten of these clones were for previously known genes: CD21, serglycin proteoglycan core, vimentin, cathepsin H, annexin VI, myristylated alanine-rich protein C kinase substrate, and CD44. Two new cDNAs, EBI1 and EBI2, encoding proteins with the features of ***G*** ***protein*** - ***coupled*** ***receptors*** were obtained. These two genes are strongly induced upon EBV infection. A third cDNA, encoding a protein with some similarity to ciliary neurotrophic factor receptor was also cloned.

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:248977 CAPLUS
DOCUMENT NUMBER: 118:248977
TITLE: Epstein-Barr virus-induced genes: First lymphocyte-specific G protein-coupled peptide receptors
AUTHOR(S): Birkenbach, Mark; Josefsen, Knud; Yalamanachili, Ramana; Lenoir, Gilbert; Kieff, Elliott
CORPORATE SOURCE: Dep. Med., Harvard Univ., Boston, MA, 02115, USA
SOURCE: Journal of Virology (1993), 67(4), 2209-20
CODEN: JOVIAM; ISSN: 0022-538X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Since Epstein-Barr virus (EBV) infection of Burkitt's lymphoma (BL) cells in vitro reproduces many of the activation effects of EBV infection of primary B lymphocytes, mRNAs induced in BL cells have been cloned and identified by subtractive hybridization. Nine genes encode RNAs which are 4- to >100-fold more abundant after EBV infection. Two of these, the genes for CD21 and vimentin, were previously known to be induced by EBV infection. Five others, the genes for cathepsin H, annexin VI (p68), serglycin proteoglycan core protein, CD44, and the myristylated alanine-rich protein kinase C substrate (MARCKS), are genes which were not previously known to be induced by EBV infection. Two novel genes, EBV-induced genes 1 and 2 (EBI 1 and ***EBI*** ***2*** , resp.) can be predicted from their cDNA sequences to encode G protein-coupled peptide

receptors. EBI 1 is expressed exclusively in B- and T-lymphocyte cell lines and in lymphoid tissues and is highly homologous to the interleukin 8 receptors. ***EBI*** ***2*** is most closely related to the thrombin receptor. ***EBI*** ***2*** is expressed in B-lymphocyte cell lines and in lymphoid tissues but not in T-lymphocyte cell lines or peripheral blood T lymphocytes. ***EBI*** ***2*** is also expressed at lower levels in a promyelocytic and a histiocytic cell line and in pulmonary tissue. These predicted G protein-coupled peptide receptors are more likely to be mediators of EBV effects on B lymphocytes or of normal lymphocyte functions than are genes previously known to be up-regulated by EBV infection.

=> d l3 ibib abs 1-2

L3 ANSWER 1 OF 1 WPIDS (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: 1999-034722 [03] WPIDS
DOC. NO. CPI: C1999-010477
TITLE: New isolated human ***G*** - ***protein*** ***coupled*** ***receptors*** - used to develop products for treating e.g. asthma, Parkinson's disease, heart failure, osteoporosis, hypertension, psychoses, eating disorders or cancers.
DERWENT CLASS: B04 D16
INVENTOR(S): LI, Y; RUBEN, S M
PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC
COUNTRY COUNT: 22
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9850549	A2	19981112	(199903)*	EN	54
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP US					
US 6060272	A	20000509	(200030)		
EP 1007670	A2	20000614	(200033)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2002508657 W		20020319	(200222)		81
US 2002052043 A1		20020502	(200234)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9850549	A2		WO 1998-US9048	19980507
US 6060272	A		US 1997-852824	19970507
EP 1007670	A2		EP 1998-920965	19980507
			WO 1998-US9048	19980507
JP 2002508657 W			JP 1998-548332	19980507
			WO 1998-US9048	19980507
US 2002052043 A1		Cont of	US 1997-852824	19970507
		Cont of	US 2000-518383	20000303
			US 2001-827937	20010409

FILING DETAILS:

PATENT NO	KIND		PATENT NO
EP 1007670	A2	Based on	WO 9850549
JP 2002508657 W		Based on	WO 9850549
US 2002052043 A1		Cont of	US 6060272

PRIORITY APPLN. INFO: US 1997-852824 19970507; US 2000-518383 20000303; US 2001-827937 20010409

AN 1999-034722 [03] WPIDS
AB WO 9850549 A UPAB: 19990310
An isolated polynucleotide (PN) is claimed which comprises a PN having at least a 95% identity to a member selected from: (a) a PN encoding a polypeptide comprising amino acids 2 to 342 of a 342 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; (b) a PN encoding a polypeptide comprising amino acids 1 to 260 of a 276 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; and (c) the complement of (a) or (b).
Also claimed are:
(1) a recombinant vector comprising a PN as above which is DNA;
(2) a recombinant host cell comprising a PN as above which is DNA;

(3) an insolated PN comprising a PN having at least a 95% identity to a member selected from: (a) PN encoding the same polypept[redacted] encoded by a human cDNA in ATCC ***209003*** ; (b) a PN encoding the same polypeptide encoded by the human cDNA in ATCC 209004; and (c) the complement of (a) or (b);

(4) a recombinant vector comprising a PN as in (3) which is DNA;

(5) a recombinant host cell comprising a PN as in (3) which is DNA;

(6) an isolated polypeptide comprising a mature polypeptide having an amino acid sequence encoded by a PN which is at least 95% identical to a member selected from (a), (b) and (c) as in (A);

(7) an antibody against a polypeptide as in (6); (8) an antagonist against a polypeptide as in (6);

(8) a polynucleotide comprising nucleotides 226-1251 of a 2249 bp sequence given in the specification or nucleotides 2-827 of a 1737 bp sequence given in the specification (both encoding ***G*** ***protein*** ***coupled*** ***receptors***).

USE - (II) is a novel human Epstein-Barr Virus (EBV)-induced ***G*** - ***protein*** ***coupled*** ***receptor*** , designated EBI-2 polypeptide. (IV) is a novel human endothelium-differentiation gene (EDG) like ***G*** - ***protein*** ***coupled*** ***receptor*** , designated EDG-1-like ***G*** - ***protein*** ***coupled*** ***receptor*** . Agonists for ***G*** - ***protein*** ***coupled*** ***receptors*** can be used for the treatment of e.g. asthma, Parkinson's disease, acute heart failure, hypotension, urinary retention and osteoporosis. Antagonists can be used for the treatment of e.g. hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, psychoses, depression, migraine, vomiting, stroke, eating disorders, migraine headaches, cancer and benign prostatic hypertrophy. The products can also be used for detection, diagnosis and drug screening.

Dwg.0/4

=> d l6 ibib abs 1-2

L6 ANSWER 1 OF 2 WPIDS (C) 2003 THOMSON DERWENT DUPLICATE 1

ACCESSION NUMBER: 1999-034722 [03] WPIDS

DOC. NO. CPI: C1999-010477

TITLE: New isolated human ***G*** - ***protein*** ***coupled*** ***receptors*** - used to develop products for treating e.g. asthma, Parkinson's disease, heart failure, osteoporosis, hypertension, psychoses, eating disorders or cancers.

DERWENT CLASS: B04 D16

INVENTOR(S): LI, Y; RUBEN, S M

PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC

COUNTRY COUNT: 22

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9850549	A2	19981112	(199903)*	EN	54
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: CA JP US					
US 6060272	A	20000509	(200030)		
EP 1007670	A2	20000614	(200033)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
JP 2002508657	W	20020319	(200222)		81
US 2002052043	A1	20020502	(200234)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9850549	A2		WO 1998-US9048	19980507
US 6060272	A		US 1997-852824	19970507
EP 1007670	A2		EP 1998-920965	19980507
			WO 1998-US9048	19980507
JP 2002508657	W		JP 1998-548332	19980507
			WO 1998-US9048	19980507
US 2002052043	A1	Cont of	US 1997-852824	19970507
		Cont of	US 2000-518383	20000303
			US 2001-827937	20010409

FILING DETAILS:

PATENT NO	KIND	PATENT NO

EP 1007670 A2 Based on WO 9850549
JP 2002508657 W Based on WO 9850549
US 2002052043 A1 Cont of US 6060272

PRIORITY APPLN. INFO: US 1997-852824 19970507; US 2000-518383 20000303; US 2001-827937 20010409

AN 1999-034722 [03] WPIDS

AB WO 9850549 A UPAB: 19990310

An isolated polynucleotide (PN) is claimed which comprises a PN having at least a 95% identity to a member selected from: (a) a PN encoding a polypeptide comprising amino acids 2 to 342 of a 342 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; (b) a PN encoding a polypeptide comprising amino acids 1 to 260 of a 276 aa ***G*** ***protein*** ***coupled*** ***receptor*** sequence given in the specification; and (c) the complement of (a) or (b).

Also claimed are:

(1) a recombinant vector comprising a PN as above which is DNA;

(2) a recombinant host cell comprising a PN as above which is DNA;

(3) an insolated PN comprising a PN having at least a 95% identity to a member selected from: (a) a PN encoding the same polypeptide encoded by a human cDNA in ATCC 209003; (b) a PN encoding the same polypeptide encoded by the human cDNA in ATCC 209004; and (c) the complement of (a) or (b);

(4) a recombinant vector comprising a PN as in (3) which is DNA;

(5) a recombinant host cell comprising a PN as in (3) which is DNA;

(6) an isolated polypeptide comprising a mature polypeptide having an amino acid sequence encoded by a PN which is at least 95% identical to a member selected from (a), (b) and (c) as in (A);

(7) an ***antibody*** against a polypeptide as in (6); (8) an antagonist against a polypeptide as in (6);

(8) a polynucleotide comprising nucleotides 226-1251 of a 2249 bp sequence given in the specification or nucleotides 2-827 of a 1737 bp sequence given in the specification (both encoding ***G*** ***protein*** ***coupled*** ***receptors***).

USE - (II) is a novel human Epstein-Barr Virus (EBV)-induced ***G*** - ***protein*** ***coupled*** ***receptor*** , designated ***EBI*** - ***2*** polypeptide. (IV) is a novel human endothelium-differentiation gene (EDG) like ***G*** - ***protein*** ***coupled*** ***receptor*** , designated EDG-1-like ***G*** - ***protein*** ***coupled*** ***receptor*** . Agonists for ***G*** - ***protein*** ***coupled*** ***receptors*** can be used for the treatment of e.g. asthma, Parkinson's disease, acute heart failure, hypotension, urinary retention and osteoporosis. Antagonists can be used for the treatment of e.g. hypertension, angina pectoris, myocardial infarction, ulcers, asthma, allergies, psychoses, depression, migraine, vomiting, stroke, eating disorders, migraine headaches, cancer and benign prostatic hypertrophy. The products can also be used for detection, diagnosis and drug screening.

Dwg.0/4

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:628002 CAPLUS
DOCUMENT NUMBER: 121:228002
TITLE: Genes induced in B lymphocytes upon infection by Epstein-Barr virus
INVENTOR(S): Birkenbach, Mark; Kieff, Elliot
PATENT ASSIGNEE(S): Brigham and Women's Hospital, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9412519	A1	19940609	WO 1993-US9636	19931008
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9453256	A1	19940622	AU 1994-53256	19931008
US 2002040133	A1	20020404	US 2001-929583	20010814

PRIORITY APPLN. INFO.:
US 1992-980518 A 19921125
WO 1993-US9636 W 19931008
US 1994-352678 A3 19941130
US 2000-536954 A1 20000328

AB Genes induced in B lymphocytes upon infection with Epstein Barr virus (EBI genes) are cloned and characterized for use in the development of diagnostic reagents and studies of the development of infection are described. Three genes, EBI 1, ***EBI*** ***2*** and EBI 3 and the proteins encoded by them, probes for detection of infection, and ***antibodies*** to the proteins are described. A cDNA bank from Epstein-Barr virus (EBV) infected BL41 cells was differentially screened using probes from infected and uninfected cells to obtain 12 clones. Ten of these clones were for previously known genes: CD21, serglycin proteoglycan core, vimentin, cathepsin H, annexin VI, myristylated alanine-rich protein C kinase substrate, and CD44. Two new cDNAs, EBI1 and EBI2, encoding proteins with the features of ***G*** ***protein*** - ***coupled*** ***receptors*** were obtained. These two genes are strongly induced upon EBV infection. A third cDNA, encoding a protein with some similarity to ciliary neurotrophic factor receptor was also cloned.

=> d his

FILE 'MEDLINE, JAPIO, BIOSIS, SCISEARCH, WPIDS, CAPLUS, EMBASE' ENTERED

L1 38111 S G-PROTEIN COUPLED RECEPTOR OR G PROTEIN COUPLED RECEPTOR OR G
L2 5 S L1 AND (EBI-2 OR EBI 2 OR EBI 2)
L3 1 L1 AND 209003
L4 3 L2 AND (ANTIBODY OR ANTIBODIES)
L5 4 DUP REM L2 (1 DUPLICATE REMOVED)
L6 2 DUP REM L4 (1 DUPLICATE REMOVED)

=